Clinical Trial Update: Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)

View source ↗

Summary

This clinical trial update evaluates whether a combined KEAP1/NFE2L2 mutation profile and pre-treatment FDG-PET/CT radiomic analysis can prognosticate outcomes …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University Hospital, Brest | Conditions: Lung Cancer Stage III, Lung Cancer Stage IV | Status: UNKNOWN